Dimerix Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Dimerix heeft een totaal eigen vermogen van A$18.2M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$32.1M en A$13.9M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	n/a
Contant	AU$22.14m
Aandelen	AU$18.19m
Totaal verplichtingen	AU$13.89m
Totaal activa	AU$32.08m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$31.9M ) DXB } overtreffen de korte termijn passiva ( A$3.4M ).

Langlopende schulden: De kortetermijnactiva DXB ( A$31.9M ) overtreffen de langetermijnschulden ( A$10.5M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: DXB is schuldenvrij.

Schuld verminderen: DXB had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: DXB heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: DXB heeft voldoende kasruimte voor 2.3 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 15.6 % per jaar.

Dimerix Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Dimerix Limited Appoints Laura Mariani to Medical Advisory Board

New major risk - Revenue size

Dimerix Limited, Annual General Meeting, Oct 01, 2024

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.21

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.45

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven